NCT03522415View on ClinicalTrials.gov

Study of Safety and Efficacy of HLX01+MTX in Patients With Rheumatoid Arthritis

PHASE3CompletedINTERVENTIONAL

Enrollment

275

Participants

Timeline

Start Date

May 28, 2018

Primary Completion Date

April 5, 2020

Study Completion Date

September 11, 2020

Conditions

Moderately to Severely Active Rheumatoid Arthritis

Interventions

DRUG

HLX01

HLX01,Recombinant Human-mouse Chimeric Anti-CD20 Monoclonal Antibody Injection is recombinant human-mouse chimeric anti-cd20 CD20 monoclonal antibody.

DRUG

Methotrexate（MTX）

Methotrexate is a slow-acting antirheumatic drug.

Trial Locations (1)

332000

Jiujiang No.1 peoples's hospital, Jiujiang

All Listed Sponsors

lead

Shanghai Henlius Biotech

INDUSTRY

NCT03522415 - Study of Safety and Efficacy of HLX01+MTX in Patients With Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter